Skip to main content

Table 2 Chemoprevention appears to prevent ER+ cancers, but has no effect on ER- cancers

From: Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis

ER status

Number of cancersa

 

Data from BCPT

Data from MORE

 

Placebo (175 breast cancers developed)

Tamoxifen (89 breast cancers developed)

Placebo (39 breast cancers developed)

Raloxifene (22 breast cancers developed)

ER-

31

38

4

9

ER+

130

41

31

10

  1. aBecause the estrogen receptor (ER) status was not know for all cancers, the numbers do not add up to the totals. Data were taken from [4,6]. BCPT, Breast Cancer Prevention Trial; MORE, Multiple Outcomes of Raloxifene.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us